Voucher Scheme

Phenomics Australia offers a voucher scheme to facilitate and encourage access to one or more Phenomics Australia facilities. This scheme is intended to further reduce the cost of access to a specific capability.

Pipeline Accelerator - Voucher Scheme

Access the Pipeline

Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, Phenomics Australia, Therapeutic Innovation Australia (TIA) and ANSTO seamlessly support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.

To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a voucher-style scheme that supports the cost of access to a broad range of advanced capabilities. In this Pipeline Accelerator round, Phenomics Australia is partnering with TIA and ANSTO’s National Deuteration Facility (NDF) to expand the list of translation expertise necessary for the discovery and translation of medical research.

This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.

Refer to the guidelines for information on eligibility, funding levels, co-investment expectations, as well as the application and funding process. All applicants are required to complete and submit the applications online. The link to the application form can be found in the guideline document. We strongly advise you to develop your application on the provided template as the online form cannot be saved and retrieved at a later date.

Applications close on Thursday 31st of October 2024, 5pm (AEST).

Voucher scheme documents

Please click on buttons below to download the appropriate documents for the current round.

Pipeline Accelerator Outcomes

All awarded Pipeline Accelerator projects will be listed here.

Round	Lead applicant	Affiliation	Project title	Phenomics Australia node ( Capability provider)
23_24_Round 2	Dr Allara Zyberberg	Murdoch Children’s Research Institute	Developing reporter lines to enhance human kidney micro-organoids	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility
23_24_Round 2	Dr Andrew Bejoy Das	Murdoch Children’s Research Institute	High-throughput identification of targets that improve kidney organoid generation protocols	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Victorian Centre for Functional Genomics
23_24_Round 2	Dr Chun Yuen Chow	The University of Queensland	A novel therapeutic intervention for genetic epilepsies using spider-venom peptides	Genome Engineering and Disease Modelling Service (UQ - AIBN).
23_24_Round 2	Dr Chengxue Qin	Monash University	Development of Humanised Mice to Improve the Translatability for Cardiopulmonary Disease	Monash Genome Modification Platform
23_24_Round 2	Prof. Deborah Marsh	University of Technology Sydney	FDA-approved therapeutic compound library screen to discover new drugs to treat ARID1A mutant ovarian cancer	ANU Centre for Therapeutic Discovery
23_24_Round 2	Dr Dilys Leung	Monash University	Identification of personalised treatment strategies for breast cancer through high-throughput screening	Victorian Centre for Functional Genomics and Monash Organoid Program
23_24_Round 2	Dr Laura Cook	University of Melbourne	A high throughput human organoid model to measure effects of co-cultured immune cells	Victorian Centre for Functional Genomics
23_24_Round 2	Dr Louise Robertson	The University of Adelaide	Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa	Phenomics Australia node: South Australia Genome Editing Facility Therapeutics Innovation Australia node: Vector and Genome Engineering Facility
23_24_Round 2	Dr Natasha Kelly Tuano	Murdoch Children’s Research Institute	Deciphering the role of the kinome in skeletal muscle and their potential use as a therapeutic target in disease	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Monash Functional Genomics Platform
23_24_Round 2	Dr Xaria X Li	The University of Queensland	Developing new tools to enable the translation of complement therapeutics for human disease	Monash Genome Modification Platform
23_24_Round 2	Dr Yuanzhao Cao	The University of Queensland	A chloride ion channel as a novel therapeutic target for ischaemic heart disease	Monash Genome Modification Platform
23_24_Round 1	Dr Suad Mohamed Abdirahman	Peter MacCallum Cancer Centre	High throughput screening to identify new therapeutic strategies for mucinous ovarian cancer patients	Victorian Centre for Functional Genomics
23_24_Round 1	Dr Nicole J. Van Bergen	Murdoch Children's Research Institute	Development of iPSC models for ASO screening for TRAPPC4 neurodevelopmental disorder	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility
23_24_Round 1	Ms Rikki Brown	Harry Perkins Institute	Generation of Oral Carcinoma Patient-Derived Organoids for Personalised Cancer Research	Perkins Cancer Biobank
23_24_Round 1	Dr Rebekah Engel	Monash University and Cabrini Health	Personalised treatment strategies for patients with early-onset metastatic colorectal cancer	Victorian Centre for Functional Genomics and Monash Functional Genomics Platform
23_24_Round 1	Dr Iva Nikolic	oNKo-Innate Pty Ltd	Methodology development for high-throughput compound screening of primary human immune cell cytotoxicity in 3D	Victorian Centre for Functional Genomics
23_24_Round 1	Dr Remy Robert	Monash University	Development of human GPCR knock-in mice for assessment of therapeutic antibodies	Melbourne Advanced Genome Editing Centre
23_24_Round 1	Dr Naisana Seyedasli	University of Sydney & Centre for Cancer Research	Establishing a targeted treatment strategy using epigenetic reprogramming against adverse EMT-induced tumour plasticity in head and neck (oral) squamous cell carcinoma	Monash Genome Modification Platform
23_24_Round 1	Dr Holly Voges	Murdoch Children's Research Institute	Developing a human induced pluripotent stem cell reporter line for heart valve disease modelling	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility
23_24_Round 1	Dr Kevin Watt	Murdoch Children's Research Institute	Generation of mouse models of inherited heart failure to test the efficacy of novel stem cell based therapies	Melbourne Advanced Genome Editing Centre
22_23_Round 2	Prof James Hudson	QIMR Berghofer	Development of an epicardial lineage tracing human pluripotent stem cell line to identify new cardiac therapeutics	Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility
22_23_Round 2	Dr Graham A. Mackay	The University of Melbourne	MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation	Victorian Centre for Functional Genomics
22_23_Round 2	Dr Brett McKinnon	The University of Queensland	High throughput screening of micro-organoids for assessing heterogeneity and precision medicine potential in endometriosis	Victorian Centre for Functional Genomics
22_23_Round 2	Dr Zhian Chen	The University of Queensland	The role of ferroptosis and oxidative stress in regulating immunity	Monash Genome Modification Platform
22_23_Round 2	Dr Svenja Pachernegg	Murdoch Children's Research Institute	Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal	Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility
22_23_Round 2	Dr Ada Koo	The University of Melbourne	Developing transcriptomic and morphological profiling of macrophages to mine the microbiome	Victorian Centre for Functional Genomics
22_23_Round 2	Dr Alexander Nicholas Combes	Monash University	New therapeutic strategies and targets to suppress acute kidney injury	Victorian Centre for Functional Genomics and Monash Functional Genomics Platform
22_23_Round 2	Dr Simon Preston	Anaxis Pharma Pty Ltd	Evaluating human organoids as model systems in drug development	Monash Organoid Program
22_23_Round 2	A/Prof Edwina McGlinn	Monash University	Tick tock, tick tock… Mechanisms pacing the Hox clock	Monash Functional Genomics Platform

Voucher Scheme Webinars

If you have any questions regarding Pipeline Accelerator, refer to our FAQs or come along to our info session on the 10th of September at 1pm. Alternatively, contact us at contact@australianphenomics.org.au

More information

For further information about the voucher scheme, please contact:

contact@australianphenomics.org.au

Pipeline Accelerator FAQs

Search for an answer here

Therapeutic Innovation Australia (TIA) is a national consortium of translational research infrastructure with a focus on the development of new therapeutic products such as biologics and vaccines, cell and gene therapies as well as small molecule pharmaceuticals. More information here.